P21 Adamantane

Compound Overview

P21 Adamantane is identified in the supplied research data as the adamantane-modified P021-style molecule used in neurotrophic pathway research models. The defining structural point is the adamantane-containing residue in the displayed structure, combined with the acetylated N-terminus and C-terminal amide described by the source record.

The compound should be understood as a research material with a specific identity profile rather than as a general P21 label. The provided warning notes that non-adamantane substitutions are common in vendor confusion around this product class. For that reason, the adamantane residue and cap state are not minor naming details; they are part of the technical identity that should be confirmed against supplier documentation, mass data, and available COA records before laboratory use.

Nexus lists this item as a 10mg research-size product under SKU PP10. No human-use, veterinary-use, therapeutic, diagnostic, disease-treatment, or dosing application is described or implied by this product page.

Research Background & Published Literature

The research background supplied for P21 Adamantane is concise. It identifies the compound as an adamantane-modified P021-style molecule and states that it is used in neurotrophic pathway research models. It also highlights the need to verify the adamantane moiety carefully because naming confusion around this product class can result in non-adamantane substitutions being treated as equivalent when they are not the same compound.

The structured source record does not provide article-level peer-reviewed citations for specific experimental outcomes. Because of that, this description does not add mechanism claims, efficacy language, model-specific results, disease context, or translational interpretation beyond the source text. Research teams evaluating P21 Adamantane should rely on their own literature review and on lot-specific analytical documentation for experimental planning.

The provided source list includes the following chemistry-oriented references:

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Bolognin et al. (2014) — Neurobiol Aging
• Kazim et al. (2014) — Neurobiol Dis
• Baazaoui et al. (2017) — Alzheimers Res Ther

Storage, Handling & Stability Guidelines

Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.

• Store sealed lyophilized material at -20°C.
• Keep material desiccated and protected from light during storage.
• Use a validated laboratory SOP and the applicable lot/source record for any preparation or post-reconstitution handling.
• Use a validated laboratory SOP and the applicable lot/source record for any preparation or post-reconstitution handling.
• Use appropriate PPE, labeling, and institutional chemical-safety controls for research reagents.
• Maintain traceability between the received vial, internal inventory record, and any available lot documentation.

No validated reconstitution solvent, concentration, post-reconstitution expiration interval, or stability-study dataset was provided in the source record. Those values should be determined only through laboratory SOPs, current supplier documentation, or lot-specific analytical records, not assumed from this description.

Quality Assurance & Lab Verification

The Certificate of Analysis for this catalog item is pending. No provisional batch, assay, method, analyst, or release data is published in this product dossier. Check the Lab Verified archive for documentation status.